Detalles de la búsqueda
1.
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Gastroenterology;
158(8): 2139-2149.e14, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32092309
2.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Gastroenterology;
158(8): 2123-2138.e8, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32044319
3.
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
J Allergy Clin Immunol;
145(3): 877-884, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31786154
4.
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Lancet;
393(10188): 2303-2311, 2019 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31130260
5.
Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
Rheumatology (Oxford);
59(11): 3303-3313, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32277824
6.
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet;
391(10139): 2503-2512, 2018 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29908669
7.
Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis.
Rheumatology (Oxford);
58(2): 352-360, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30376130
8.
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
Rheumatology (Oxford);
57(11): 1972-1981, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30032191
9.
Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis.
Drug Metab Dispos;
46(4): 429-439, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29348125
10.
Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
Br J Clin Pharmacol;
83(10): 2242-2248, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28503781
11.
Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
Br J Clin Pharmacol;
82(1): 160-7, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26991517
12.
Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.
Br J Clin Pharmacol;
82(5): 1333-1342, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27333593
13.
Dynamic visceral ischemia in type A dissection.
J Card Surg;
36(3): 1136-1137, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33491245
14.
Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
Br J Clin Pharmacol;
78(1): 94-105, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24433449
15.
The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.
Br J Clin Pharmacol;
77(6): 965-74, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24215171
16.
Feasibility of Using Population Pharmacokinetics-Based Virtual Control Groups in Organ Impairment Studies.
J Clin Pharmacol;
2024 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38346862
17.
Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment.
J Clin Pharmacol;
2024 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38520128
18.
Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
Clin Pharmacol Drug Dev;
2024 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38346861
19.
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.
Clin Pharmacokinet;
2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578394
20.
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors.
J Immunother Cancer;
12(4)2024 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38604815